Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T34296 | Target Info | |||
| Target Name | Matrix metalloproteinase-13 (MMP-13) | ||||
| Synonyms |
Matrix metalloproteinase 13; Collagenase-3; Collagenase 3
Click to Show/Hide
|
||||
| Target Type | Clinical trial Target | ||||
| Gene Name | MMP13 | ||||
| Biochemical Class | Peptidase | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Matrix metalloproteinase-1 (MMP-1) | Successful Target | ||||
| UniProt ID | MMP1_HUMAN | |||||
| Gene Name | MMP1 | |||||
| Synonyms |
Interstitial collagenase; Fibroblast collagenase; CLG
Click to Show/Hide
|
|||||
| Representative Drug(s) | Apratastat | Drug Info | IC50 = 33 nM | [1] | ||
| Co-Target Name | Amyloid beta A4 protein (APP) | Successful Target | ||||
| UniProt ID | A4_HUMAN | |||||
| Gene Name | APP | |||||
| Synonyms |
Protease nexin-II; PreA4; PN-II; Cerebral vascular amyloid peptide; CVAP; Amyloid-beta precursor protein; Amyloid-beta A4 protein; Alzheimer disease amyloid protein; APPI; APP; AD1; ABPP; A4
Click to Show/Hide
|
|||||
| Representative Drug(s) | Curcumin | Drug Info | IC50 = 630 nM | [2] | ||
| Co-Target Name | Monoamine oxidase type A (MAO-A) | Successful Target | ||||
| UniProt ID | AOFA_HUMAN | |||||
| Gene Name | MAOA | |||||
| Synonyms |
Monoamine oxidase A; Amine oxidase [flavin-containing] A
Click to Show/Hide
|
|||||
| Representative Drug(s) | Curcumin | Drug Info | Ki = 710 nM | [3] | ||
| Co-Target Name | TNF alpha converting enzyme (ADAM17) | Clinical trial Target | ||||
| UniProt ID | ADA17_HUMAN | |||||
| Gene Name | ADAM17 | |||||
| Synonyms |
TNFalpha converting enzyme; TNF-alpha-converting enzyme; TNF-alpha converting enzyme; TNF-alpha convertase; TACE; Snake venom-like protease; Disintegrin and metalloproteinase domain-containing protein 17; CSVP; CD156b antigen; CD156b; ADAM 17; A disintegrin and metalloproteinase domain 17
Click to Show/Hide
|
|||||
| Representative Drug(s) | Apratastat | Drug Info | IC50 = 4 nM | [4] | ||
| Co-Target Name | Lactoylglutathione lyase (GLO1) | Clinical trial Target | ||||
| UniProt ID | LGUL_HUMAN | |||||
| Gene Name | GLO1 | |||||
| Synonyms |
S-D-lactoylglutathione methylglyoxal lyase; Methylglyoxalase; Ketone-aldehyde mutase; Glyoxalase I; GlxI; Glx I; GLO1; Aldoketomutase
Click to Show/Hide
|
|||||
| Representative Drug(s) | Curcumin | Drug Info | Ki = 5 nM | [5] | ||
| Co-Target Name | Tissue factor (F3) | Successful Target | ||||
| UniProt ID | TF_HUMAN | |||||
| Gene Name | F3 | |||||
| Synonyms |
Thromboplastin; TF; F3; Coagulation factor III; CD142 antigen
Click to Show/Hide
|
|||||
| Representative Drug(s) | Curcumin | Drug Info | IC50 = 13.16 nM | [6] | ||
| Co-Target Name | Matrix metalloproteinase-14 (MMP-14) | Clinical trial Target | ||||
| UniProt ID | MMP14_HUMAN | |||||
| Gene Name | MMP14 | |||||
| Synonyms |
Membrane-type-1 matrix metalloproteinase; Membrane-type matrix metalloproteinase 1; MTMMP1; MT1MMP; MT1-MMP; MT-MMP 1; MMP-X1
Click to Show/Hide
|
|||||
| Representative Drug(s) | PMID17935984C1 | Drug Info | IC50 = 22.91 nM | [7] | ||
| Co-Target Name | Prostaglandin E synthase (PTGES) | Clinical trial Target | ||||
| UniProt ID | PTGES_HUMAN | |||||
| Gene Name | PTGES | |||||
| Synonyms |
p53-induced gene 12 protein; PIG12; PGES; PGE synthase; P53-induced apoptosis protein 12; Microsomal prostaglandin E synthase 1; Microsomal glutathione S-transferase 1-like 1; MPGES1; MPGES-1; MGST1L1; MGST1-L1
Click to Show/Hide
|
|||||
| Representative Drug(s) | Curcumin | Drug Info | IC50 = 200 nM | [8] | ||
| Co-Target Name | CDGSH iron-sulfur domain-containing protein 1 (CISD1_HUMAN) | Co-Target | ||||
| UniProt ID | CISD1_HUMAN | |||||
| Gene Name | CISD1 | |||||
| Synonyms |
MitoNEET
Click to Show/Hide
|
|||||
| Representative Drug(s) | Curcumin | Drug Info | Ki = 101 nM | [9] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. | ||||
| REF 2 | Neuritogenic activity of bi-functional bis-tryptoline triazole. Bioorg Med Chem. 2017 Feb 1;25(3):1195-1201. | ||||
| REF 3 | Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis. ACS Med Chem Lett. 2015 Dec 1;7(1):56-61. | ||||
| REF 4 | Identification of novel TACE inhibitors compatible with topical application. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1848-53. | ||||
| REF 5 | Recent advances in the discovery and development of glyoxalase I inhibitors. Bioorg Med Chem. 2020 Feb 15;28(4):115243. | ||||
| REF 6 | Microbial hydroxylation and glycosylation of pentacyclic triterpenes as inhibitors on tissue factor procoagulant activity. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1026-30. | ||||
| REF 7 | Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007 Mar 15;15(6):2223-68. | ||||
| REF 8 | Targeting microsomal prostaglandin E2 synthase-1 (mPGES-1): the development of inhibitors as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs). Medchemcomm. 2015;6:2081-123. | ||||
| REF 9 | Identification of small molecules that bind to the mitochondrial protein mitoNEET. Bioorg Med Chem Lett. 2016 Nov 1;26(21):5350-5353. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.